Tailored chemo may boost survival in bile duct cancer patients
NCT ID NCT07296666
First seen Jan 04, 2026 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests whether using a 3D-PTA drug sensitivity test to choose chemotherapy after surgery can help people with stage II/III bile duct cancer live longer without the cancer returning. About 98 adults who have had their tumor removed will be randomly assigned to either standard chemo or a personalized chemo regimen based on the test. The goal is to see if personalized treatment improves outcomes compared to standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.